<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271450</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000215</org_study_id>
    <nct_id>NCT03271450</nct_id>
  </id_info>
  <brief_title>The DARE Warfarin CER Study</brief_title>
  <official_title>The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately half a million Americans annually experience venous thromboembolic disease,&#xD;
      including deep venous thrombosis (DVT) and pulmonary embolism (PE). Since 2010, four new oral&#xD;
      anticoagulants have been approved for marketing in addition to the vitamin K antagonist&#xD;
      warfarin. Very limited head-to-head data exists comparing these treatment options, leaving&#xD;
      patients, clinicians, and other stakeholders with little guidance for selecting the best&#xD;
      strategy that balances recurrence reduction with risk of bleeding. In the DARE Warfarin CER&#xD;
      Study, the researchers compare all five currently available oral anticoagulant agents for the&#xD;
      extended treatment of DVT and PE, as well as no extended treatment. This study also aims to&#xD;
      evaluate whether treatment heterogeneity exists for specific populations, such as older&#xD;
      patients or those with renal dysfunction. In a secondary aim, the study will also leverage a&#xD;
      database of linked electronic health record-insurance claims to validate diagnosis&#xD;
      definitions and account for potential residual confounding by factors unmeasured in claims&#xD;
      data. As the patient population includes all Medicare novel anticoagulant users and large&#xD;
      numbers of commercially insured and Medicaid patients, the results will likely be&#xD;
      transportable to the majority of US patients experiencing a DVT or PE. Pursuant to the&#xD;
      objectives of the Patient-Centered Outcomes Research Institute, a study advisory committee&#xD;
      consisting of key stakeholders will be actively involved in the study design and&#xD;
      dissemination of results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Safety Outcome: Intracranial bleed, Gastrointestinal bleed, Other Major bleed</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Defined as a new episode of either Intracranial bleed, Gastrointestinal bleed or another Major bleed event during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Effectiveness Outcome: Deep Venous Thrombosis, Pulmonary Embolism</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Defined as a new episode of either Deep Venous Thrombosis or Pulmonary Embolism during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Measured after index prescription date + 90 days and on date on which the event occurred and defined as hospitalization with discharge status code of: 20, 22-29, 40-42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite safety and effectiveness outcome</measure>
    <time_frame>1-2 years</time_frame>
    <description>defined as earlier of safety or DVT/PE outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite safety and effectiveness outcome, including death</measure>
    <time_frame>1-2 years</time_frame>
    <description>Measured after index prescription date + 90 days and on date on which the event occurred and defined as hospitalization with discharge status code of: 20, 22-29, 40-42</description>
  </primary_outcome>
  <number_of_groups>30</number_of_groups>
  <enrollment type="Anticipated">416000</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Warfarin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort derived from a commercial database, MarketScan, and Medicare Research Identifiable&#xD;
        Files using data from 2009-2015. Cohort data will be updated as new data come in through&#xD;
        2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Inpatient stay with diagnosis code of DVT/PE (see Appendix A), 1/1/2010 - 9/30/2015&#xD;
             for which the patient has at least 365 days continuous medical and pharmacy&#xD;
             eligibility prior and no other inpatient stays with DVT/PE diagnosis. Set discharge&#xD;
             date as index diagnosis date. Take only the first eligible episode for a patient, if&#xD;
             multiple.&#xD;
&#xD;
          2. Prescription fill for an anticoagulant [generic name=dabigatran (150mg), apixaban&#xD;
             (2.5mg, 5mg, 10mg), rivaroxaban (15mg, 20mg), edoxaban (30mg, 60mg), or warfarin]&#xD;
             within 30 days of and including index diagnosis date. Set earliest anticoagulant&#xD;
             prescription as index generic and date as index rx date.&#xD;
&#xD;
          3. No anticoagulant prescription fill in the 365 days prior to index diagnosis date.&#xD;
&#xD;
          4. Continuous enrollment and use of an anticoagulant for the first 90 days including and&#xD;
             following the index rx date, defined as no gaps in therapy &gt;7 days. For each patient,&#xD;
             assign a variable to indicate whether the patient filled an anticoagulant with a&#xD;
             different generic name as index during this period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any safety outcome between index diagnosis date and index rx date + 90, defined as:&#xD;
             intracranial bleed, gastrointestinal bleed, or other major bleed.&#xD;
&#xD;
          2. Any DVT/PE between index diagnosis date and index rx date + 90.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Katsiaryna Bykov, PharmD, ScD</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>warfarin</keyword>
  <keyword>apixaban</keyword>
  <keyword>edoxaban</keyword>
  <keyword>extended treatment</keyword>
  <keyword>oral anticoagulant</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>comparative safety</keyword>
  <keyword>comparative effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

